Active Broker’s Concerns In Focus: Brinker International (NYSE:EAT), Gevo (NASDAQ:GEVO)

Brinker International, Inc. (NYSE:EAT) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 0.68% to close at $47.16 with the total traded volume of 3.43 Million shares. Brinker International Inc. (EAT) declared that its fiscal Q4 net income of $34.6 million. On a per-share basis, the Dallas-based company said it had profit of 69 cents. Earnings, adjusted for non-recurring costs, came to 71 cents per share. The results did not meet Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 75 cents per share.

The operator of restaurant chains Chili’s Grill & Bar and Maggiano’s Little Italy posted revenue of $771 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $794.7 million. Brinker International expects full-year earnings in the range of $3.05 to $3.15 per share. Its price to sales ratio ended at 0.72. EAT attains analyst recommendation of 3.00 with week’s performance of 0.81%.

Gevo, Inc. (NASDAQ:GEVO) [Trend Analysis] moved down reacts as active mover, shares a decrease -1.93% to traded at $3.05 and the percentage gap between open changing to regular change was 1.29%. Gevo, Inc. (GEVO) reported that it has received a letter from The NASDAQ Stock Market LLC notifying the Company that it has regained compliance with the NASDAQ Capital Market’s minimum bid price continued listing requirement.

The letter noted that as of January 20, 2017, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with NASDAQ Marketplace Rule 5550(a)(2) and NASDAQ considers the matter closed. The firm’s current ratio calculated as 0.90 for the most recent quarter. The firm past twelve months price to sales ratio was 0.77 and price to cash ratio remained 0.71. As far as the returns are concern, the return on equity was recorded as -77.70% and return on investment was -35.20% while its return on asset stayed at -40.50%. The firm has total debt to equity ratio measured as 0.51.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *